Granata Bio has acquired Oviva Therapeutics Inc., a women’s health biotech company focused on advancing treatments that address female physiology, with an emphasis on ovarian aging.

Oviva’s lead candidate, OVI-586, is a first-in-class therapeutic designed to enhance women’s health span—the period of life spent in optimal health—by extending ovarian function. OVI-586 holds potential applications across menopause, contraception, and in vitro fertilization (IVF), offering new possibilities for patients seeking advanced reproductive and endocrine health solutions.

“The acquisition of Oviva Therapeutics marks a significant milestone in our efforts to bring forward new therapies for those with limited treatment options,” said Evan Sussman, Co-Founder and CEO of Granata Bio. “In IVF stimulation, OVI-586 offers a biologically grounded approach to improving ovarian response—even in patients with diminished ovarian reserve. We’re excited to continue advancing OVI-586 and explore its potential in assisted reproductive technology (ART) and beyond.”

Other Pharma Industry Acquisitions

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.